Somatic POLE proofreading domain mutation, immune response and prognosis in colorectal cancer: a retrospective, pooled biomarker study
Background<br/> Precision cancer medicine depends on defining distinct tumour subgroups using biomarkers that may occur at very modest frequencies. One such subgroup comprises patients with exceptionally mutated (ultramutated) cancers caused by mutations that impair DNA polymerase epsilon (POL...
Principais autores: | Domingo, E, Freeman-Mills, L, Rayner, E, Glaire, M, Briggs, S, Koelzer, V, Frangou, E, Dutton, P, Kerr, R, Kerr, D, Tomlinson, I, Church, D, EPICOLON consortium |
---|---|
Formato: | Journal article |
Publicado em: |
Lancet
2016
|
Registros relacionados
-
POLE proofreading domain mutation defines a subset of immunogenic colorectal cancers with excellent prognosis
por: Glaire, MA, et al.
Publicado em: (2016) -
POLE proofreading mutation, immune response and prognosis in endometrial cancer
por: Van Gool, I, et al.
Publicado em: (2015) -
POLE proofreading mutations elicit an anti-tumor immune response in endometrial cancer
por: Klenerman, P, et al.
Publicado em: (2015) -
Adjuvant treatment for POLE proofreading domain-mutant cancers: sensitivity to radiotherapy, chemotherapy, and nucleoside analogues
por: Van Gool, I, et al.
Publicado em: (2018) -
A panoply of errors: polymerase proofreading domain mutations in cancer
por: Rayner, E, et al.
Publicado em: (2016)